Dan Grandér's Group
Molecular mechanisms of action of anti-cancer drugs and role of non-coding RNA in cancer
The aim of our research is to improve conditions for the use of anti-cancer drugs in patients with cancer. The group runs two major projects: studies on the mechanisms of cell death (and resistance) induced by well-known as well as novel anti-cancer drugs and the role of non-coding RNA in cancer.
Our research team is working with RNAi prodrugs to study Polo-like kinases (Plks) as cancer therapy targets in pediatric leukemia, breast and ovarian cancer.